[Acalabrutinib (previously untreated chronic lymphocytic leukaemia; combination with obinutuzumab) - Addendum to Commission A20-104]
Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018003884
German
Original Title:
Acalabrutinib (nicht vorbehandelte chronische lymphatische Leukaemie; Kombination mit Obinutuzumab) - Addendum zum Auftrag A20-104
Details
Project Status:
Completed
URL for project:
https://www.iqwig.de/projekte/a21-53.html
Year Published:
2021
URL for published report:
https://www.iqwig.de/download/a21-53_acalabrutinib_addendum-zum-auftrag-a20-104_v1-0.pdf
English language abstract:
There is no English language summary available
Publication Type:
Full HTA
Country:
Germany
MeSH Terms
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Antineoplastic Agents
- Antibodies, Monoclonal, Humanized
- Tyrosine Kinase Inhibitors
- Antineoplastic Agents, Immunological
Keywords
- Acalabrutinib
- Leukemia ? Lymphocytic ? Chronic ? B-Cell
- Benefit Assessment
- NCT02475681
Contact
Organisation Name:
Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address:
IQWiG, Siegburger Str. 237, 50679 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email:
berichte@iqwig.de
Copyright:
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.